Nutrition in Clinical Practice

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Siddiqui, R.
Right arrow Articles by Zaloga, G. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Siddiqui, R.
Right arrow Articles by Zaloga, G. P.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Nutrition in Clinical Practice, Vol. 21, No. 2, 155-167 (2006)
DOI: 10.1177/0115426506021002155
© 2006 The American Society for Parenteral and Enteral Nutrition

Invited Review

Nutrition Modulation of Cachexia/Proteolysis

Rafat Siddiqui, PhD*,{dagger}, Darshak Pandya, DO*,{dagger}, Kevin Harvey, BS* and Gary P. Zaloga, MD*,{dagger}

* Methodist Research Institute of Clarian Health Partners, Indianapolis, Indiana; and the{dagger} Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana

Correspondence: Gary P. Zaloga, MD, Medical Director, Methodist Research Institute, 1812 N Capitol Ave, Wile Hall, Room 120, Indianapolis, IN 46202. Electronic mail may be sent to gzaloga{at}clarian.org.

Cachexia represents progressive wasting of muscle and adipose tissue and is associated with increased morbidity and mortality. Although anorexia usually accompanies cachexia, cachexia rarely responds to increased food intake alone. Our knowledge of the underlying mechanisms responsible for cachexia remains incomplete. However, most states of cachexia are associated with underlying inflammatory processes and/or cancer. These processes activate protein degradation and lipolytic pathways, resulting in tissue loss. In this article, we briefly review the pathophysiology of cachexia and discuss the role of specific nutrient supplements for the treatment of cachexia. The branched chain amino acid leucine, the leucine metabolite β-hydroxy-β-methylbutyrate, arginine, glutamine, {omega}-3 long chain fatty acids, conjugated linoleic acid, and polyphenols have demonstrated some efficacy in animal and/or human studies. Optimal treatment for cachexia is likely aimed at maximizing muscle and adipose synthesis while minimizing degradation.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Nutr Clin PractHome page
R. A. Siddiqui, K. A. Harvey, G. P. Zaloga, and W. Stillwell
Modulation of Lipid Rafts by {Omega}-3 Fatty Acids in Inflammation and Cancer: Implications for Use of Lipids During Nutrition Support
Nutr Clin Pract, February 1, 2007; 22(1): 74 - 88.
[Abstract] [Full Text] [PDF]